RESUMEN
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
RESUMEN
To discover novel genes underlying amyotrophic lateral sclerosis (ALS), we aggregated exomes from 3,864 cases and 7,839 ancestry-matched controls. We observed a significant excess of rare protein-truncating variants among ALS cases, and these variants were concentrated in constrained genes. Through gene level analyses, we replicated known ALS genes including SOD1, NEK1 and FUS. We also observed multiple distinct protein-truncating variants in a highly constrained gene, DNAJC7. The signal in DNAJC7 exceeded genome-wide significance, and immunoblotting assays showed depletion of DNAJC7 protein in fibroblasts in a patient with ALS carrying the p.Arg156Ter variant. DNAJC7 encodes a member of the heat-shock protein family, HSP40, which, along with HSP70 proteins, facilitates protein homeostasis, including folding of newly synthesized polypeptides and clearance of degraded proteins. When these processes are not regulated, misfolding and accumulation of aberrant proteins can occur and lead to protein aggregation, which is a pathological hallmark of neurodegeneration. Our results highlight DNAJC7 as a novel gene for ALS.
Asunto(s)
Esclerosis Amiotrófica Lateral/genética , Exoma/genética , Predisposición Genética a la Enfermedad/genética , Proteínas de Choque Térmico/genética , Chaperonas Moleculares/genética , Estudios de Casos y Controles , Femenino , Variación Genética/genética , Humanos , MasculinoRESUMEN
In the past few years, a plethora of methods for rare variant association with phenotype have been proposed. These methods aggregate information from multiple rare variants across genomic region(s), but there is little consensus as to which method is most effective. The weighting scheme adopted when aggregating information across variants is one of the primary determinants of effectiveness. Here we present a systematic evaluation of multiple weighting schemes through a series of simulations intended to mimic large sequencing studies of a quantitative trait. We evaluate existing phenotype-independent and phenotype-dependent methods, as well as weights estimated by penalized regression approaches including Lasso, Elastic Net, and SCAD. We find that the difference in power between phenotype-dependent schemes is negligible when high-quality functional annotations are available. When functional annotations are unavailable or incomplete, all methods suffer from power loss; however, the variable selection methods outperform the others at the cost of increased computational time. Therefore, in the absence of good annotation, we recommend variable selection methods (which can be viewed as "statistical annotation") on top of regions implicated by a phenotype-independent weighting scheme. Further, once a region is implicated, variable selection can help to identify potential causal single nucleotide polymorphisms for biological validation. These findings are supported by an analysis of a high coverage targeted sequencing study of 1,898 individuals.
Asunto(s)
Biología Computacional , Variación Genética/genética , Anotación de Secuencia Molecular , Sitios de Carácter Cuantitativo , Estudio de Asociación del Genoma Completo , Genómica , Genotipo , Humanos , Modelos Genéticos , Fenotipo , Polimorfismo de Nucleótido Simple/genéticaRESUMEN
Empirical evidences suggest that both common and rare variants contribute to complex disease etiology. Although the effects of common variants have been thoroughly assessed in recent genome-wide association studies (GWAS), our knowledge of the impact of rare variants on complex diseases remains limited. A number of methods have been proposed to test for rare variant association in sequencing-based studies, a study design that is becoming popular but is still not economically feasible. On the contrary, few (if any) methods exist to detect rare variants in GWAS data, the data we have collected on thousands of individuals. Here we propose two methods, a weighted haplotype-based approach and an imputation-based approach, to test for the effect of rare variants with GWAS data. Both methods can incorporate external sequencing data when available. We evaluated our methods and compared them with methods proposed in the sequencing setting through extensive simulations. Our methods clearly show enhanced statistical power over existing methods for a wide range of population-attributable risk, percentage of disease-contributing rare variants, and proportion of rare alleles working in different directions. We also applied our methods to the IFIH1 region for the type 1 diabetes GWAS data collected by the Wellcome Trust Case-Control Consortium. Our methods yield p values in the order of 10⻳, whereas the most significant p value from the existing methods is greater than 0.17. We thus demonstrate that the evaluation of rare variants with GWAS data is possible, particularly when public sequencing data are incorporated.